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 Introduction 
 Low-grade endometrial stromal sarcomas (LG-ESS) are a type of 
uterine sarcoma. Uterine sarcomas are a heterogeneous group of rare 
tumors of the uterine musculature and uterine connective tissue, and 
in accordance with the current World Health Organization (WHO) 
classification, they are distinguished from malignant mesenchymal 
tumors and malignant mixed epithelial-mesenchymal tumors and 
classified into the following entities  [1, 2] : leiomyosarcoma, LG-ESS, 
high-grade endometrial stromal sarcoma (HG-ESS), undifferentiated 
uterine sarcoma (UUS), adenosarcoma, rhabdomyosarcoma, and 
malignant-type perivascular epithelioid cell tumor.
 There are also extremely rare forms such as angiosarcomas, 
neurogenic sarcomas, osteosarcomas, chondrosarcomas, liposarco-
mas, myxofibrosarcomas, alveolar soft tissue sarcomas, epithelioid 
sarcomas, and primitive neuroectodermal tumors. In the WHO 
classification, these are assigned to the soft tissue sarcomas  [3] . 
Uterine carcinosarcomas (also known as malignant mixed Mülle-
rian tumors) were also formerly included in the group of uterine 
sarcomas. Nowadays, however, they are assigned to the group of 
uterine carcinomas  [4] .
 The diagnosis and treatment of uterine sarcomas has recently 
been reviewed in the German guideline  Sarcoma of the Uterus. 
Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, 
August 2015)  [4] .
 Endometrial stromal sarcomas (ESS) represent only around 
0.2% of all uterine malignancies, but they make up approximately 
7–25% of uterine sarcomas  [5–8] . The annual incidence is 0.19 per 
100,000 women, and a gradual increase has been observed in the 
past  [9] . ESS is considered to be the second most frequent type of 
uterine mesenchymal neoplasia after uterine leiomyosarcoma.
 In the current WHO classification published in 2014, LG-ESS 
are classified as endometrial stromal tumors, along with benign en-
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 Abstract 
 Like other uterine sarcomas, low-grade endometrial stro-
mal sarcomas (LG-ESS) are a very rare tumor entity. In 
the past, research studies therefore discussed the vari-
ous different types of the disease in combination. In ad-
dition, the classification of endometrial stromal tumors 
presented difficulties for quite some time so that in ear-
lier studies it was not always possible to precisely distin-
guish between LG-ESS, high-grade endometrial stromal 
sarcoma, and undifferentiated uterine sarcoma. For LG-
ESS, surgery with hysterectomy and adnexectomy is the 
first-line treatment. The benefits of lymphadenectomy 
and tumor debulking are unclear. Endocrine therapy 
with gestagens and aromatase inhibitors is under dis-
cussion to provide adjuvant treatment for patients with 
advanced stages of the disease. As radiotherapy only 
provides locoregional control, and in view of the usually 
good prognosis of patients with LG-ESS, its benefits 
need to be weighed against its side effects. In the case of 
recurrence, repeat surgery is the first choice. Further re-
search studies viewing LG-ESS as a distinct entity are 
needed in order to improve treatment options for pa-
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dometrial stromal nodules (ESN), HG-ESS, and UUS. ESS are 
staged along with uterine leiomyosarcomas in accordance with the 
FIGO and TNM classifications ( table 1 )  [2, 10] .
 Tumor stage is the most important prognostic factor in LG-ESS  [11] , 
followed by the patient’s age. Another unfavorable factor that has been 
discussed is uterine morcellation  [12–14] . The relevance of mitotic rate, 
evidence of p53, and tumor necrosis is unclear  [7, 11, 15, 16] .
 In addition to arising in the uterus, LG-ESS can also develop in 
extrauterine locations such as the ovaries, the pelvis, or the abdom-
inal cavity, and also the vagina or vulva  [17] . Endometriosis is 
found in 50% of these cases, giving rise to the suspicion that stro-
mal sarcomas can develop out of endometriosis  [18] .
 Approximately 65% of the patients are FIGO stage I–II at the 
time of diagnosis, and around 35% have FIGO stage III–IV  [19] . In 
patients with tumor stage I–II, the 5-year survival rate is over 90%, 
while with stages III–IV it is around 50%.
 Classification of Endometrial Stromal Tumors 
 The classification of endometrial stromal tumors has been ex-
tremely difficult for many decades. These tumors were initially dif-
ferentiated mainly on the basis of mitoses per 10 high-powered 
fields (HPF). A mitotic index of < 10/10 HPF was associated with a 
100% 5-year survival rate, whereas with a mitotic index of > 10/10 
HPF the figure was only 55%  [20] . However, it has been known 
since as early as 1982 that the number of mitoses does not correlate 
with prognostic validity, making it unsatisfactory and impractica-
ble as a distinguishing criterion. This type of classification is there-
fore regarded in the literature as obsolete  [18, 21] . In 1990, Chang 
et al.  [22]  drew a distinction between ESS grade 1, 2, or 3 and un-
differentiated sarcomas. Kurihara et al.  [23]  proposed a distinction 
between LG-ESS, undifferentiated endometrial sarcomas with nu-
clear uniformity (UES-U), and undifferentiated endometrial sarco-
mas with nuclear pleomorphism (UES-P). In 2012, Lee et al.  [24–
27]  achieved a breakthrough by demonstrating a genomic rear-
rangement that led to a fusion of  YWHAE and  FAM22A/B through 
a translocation of chromosomes 10 and 17 (t(10; 17)). This 14–3-3 
oncoprotein appears to be highly specific for HG-ESS. It was hoped 
that this genetic feature would make it possible to distinguish be-
tween LG-ESS and HG-ESS. The WHO, having in the meantime 
abandoned the term ‘high-grade stromal sarcoma’, thus reintro-
duced the category of HG-ESS in the 2014 classification. Currently, 
a distinction is now made between LG-ESS, HG-ESS, and UUS. 
ESS and UUS are distinguished on the basis of morphologic, im-
munohistochemical, and molecular-pathologic criteria  [4] .
 Pathology 
 The cut surface of LG-ESS is yellowish to yellowish-brown, and 
may also be partly pinkish  [18] . LG-ESS can grow intramurally or 
submucosally, with unclear margins relative to the surrounding tis-
sue  [27] . Polypoid growth may lead to displacement of the uterine 
cavity when the findings are extensive  [18] .
 As malignant tumors, LG-ESS arise from mesenchymal cells 
that resemble the endometrial stroma in the proliferation phase 
 [2] . Evidence of intratumoral hemorrhage and/or necrosis varies. 
Typical findings consist of numerous small, uniform cells with lin-
guiform infiltration into the myometrium and into blood and 
lymph vessels  [18, 27] . The number of mitoses varies but is usually 
in the low range (<  5/10 HPF), although larger numbers do not 
exclude the diagnosis  [18, 27] . It may be difficult to distinguish be-
tween LG-ESS with focal glandular differentiation on the one hand 
and endometriosis on the other  [28] . They can be distinguished 
from ESN by examining their mitotic activity, which is usually 
lower in ESN  [4, 29] . Infiltration of the myometrium is not ob-
served with ESN, but finger-like projections into the neighboring 
myometrium are accepted if there are fewer than 3 and they are 
smaller than 3 mm  [27] .
 Additional immunohistochemical examinations and molecular-
pathologic analyses may make it easier to establish a diagnosis. Ma-
jority expression of CD10 and WT1 has been reported  [4, 30] . Reich 
et al.  [31]  noted high levels of expression of estrogen and progester-
one receptors in 71 and 95% of cases, respectively. Most ESS express 
aromatases  [32] . Their expression is associated with tumor growth 
and may also be relevant to the high recurrence rate  [32] . The tu-
mors also sometimes express gonadotrophin-releasing hormone 
(GnRH) receptors  [18] . One therapeutic approach that may be con-
sidered is therefore treatment with gestagens, aromatase inhibitors, 
and GnRH analogues. Around 45% of the tumors express androgen 
receptors  [33] . Evidence of smooth-muscle actin, β-catenin, and 
pancytokeratins is also possible, whereas CD117 is negative  [4] . Cy-
clin D1 shows variable and heterogeneous nuclear expression in 
< 10% of the tumor cells and may be important for distinguishing 
between these lesions and HG-ESS  [1, 4] .
 LG-ESS are a group of lesions with heterogeneous molecular-
pathologic findings, but several genetic changes observed in them 
 Table 1.  FIGO/TNM staging of uterine leiomyosarcomas and endometrial 
stromal sarcomas
FIGO stage TN M stage Definition
I/T1 tumor limited to the uterus
IA/T1a ≤ 5 cm at its largest diameter
IB/T1b > 5 cm at its largest diameter
II/T2 tumor extends beyond the uterus to the pelvis
IIA/T2a involvement of the adnexa of the uterus (unilateral 
or bilateral)
IIB/T2b tumor spread to extrauterine pelvic tissue excluding 
the adnexa
III/T3 tumor has infiltrated abdominal tissues
IIIA/T3a 1 site
IIIB/T3b more than 1 site
IIIC metastasis to the pelvic and/or para-aortic lymph 
nodes
IV/T4 IVA/T4 tumor has infiltrated the bladder and/or rectum
IVB distant metastasis
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are important, such as the translocation t(7; 17)(p15;q21) with fu-
sion of  JAZFI–SUZ12  and the fusion genes  JAZF1–PHF1 and more 
rarely  EPC1–PHF1 ,  MEAF6–PHF1 ,  ZC3H7–BCOR , and  MBTD–
CXorf67  [27] . A p53 mutation may be found in about one-quarter 
of ESS; research has shown that changes in p53 may play an impor-
tant role in the carcinogenesis in these tumors, although they have 
no influence on prognosis  [34] .
 Clinical Presentation 
 ESS typically develop in premenopausal and perimenopausal 
women with a mean age of 46 (range 18–83 years)  [22] . Rare cases 
have been reported of the tumor developing in connection with ta-
moxifen or estrogen administration, as well as after radiotherapy 
 [35, 36] . Obesity, diabetes mellitus, and early menarche are re-
ported to be associated with an increased risk of LG-ESS  [17] .
 These tumors often become apparent through pathologic vagi-
nal bleeding, sometimes also combined with uterine enlargement 
and associated symptoms such as lower abdominal pain  [2, 22] .
 Diagnosis 
 In contrast to carcinomas of the endometrium, a diagnosis of 
LG-ESS as a mesenchymal tumor cannot be securely established 
using hysteroscopy and fractional curettage. In addition, a clear 
distinction from benign ESN can only be reliably made after histo-
logical analysis of the tumor’s entire interface with the neighboring 
myometrium  [17] . Imaging procedures such as ultrasound, com-
puted tomography, and magnetic resonance imaging are not able 
to display any specific characteristics of LG-ESS  [37] .
 Surgical Treatment 
 The primary treatment for LG-ESS is surgery with total hysterec-
tomy (without morcellation) and bilateral salpingo-oophorectomy 
 [4] . Cytoreduction is recommended in advanced tumors with extra-
uterine manifestations  [38, 39] . However, Leath et al.  [40]  do not re-
gard this as offering any survival advantage in patients with LG-ESS, 
and in these cases the extent of surgery has to be decided on an indi-
vidual basis, depending on symptoms and with palliative intent.
 It has been shown that LG-ESS are hormone-dependent  [12] . It is 
not clear whether the ovaries can be preserved in young, premeno-
pausal women. Several studies have found a significantly increased 
rate of recurrence when the ovaries were preserved in premenopausal 
women  [41–43] . In addition, LG-ESS have high levels of steroid re-
ceptors and metastasize most frequently from the uterus to the ova-
ries. A Surveillance Epidemiology and End Results (SEER) analysis 
did not show any negative effects on overall survival when the ovaries 
were preserved in premenopausal patients  [44] . The decision whether 
or not to preserve the ovaries therefore always needs to be critically 
discussed with the patient, with the potential advantage of preserving 
the ovaries being carefully weighed against the increased risk of re-
currence. In view of the tumor biology of LG-ESS, estrogen therapy 
after bilateral oophorectomy cannot be recommended  [45] .
 Involvement of the pelvic and para-aortic lymph nodes does not 
appear to have any influence on prognosis. In the study by Chan et 
al. [19] , lymphadenectomy was not associated with any significant 
improvement in survival, but almost 10% of the patients who un-
derwent lymphadenectomy had lymph node metastases. Other au-
thors have taken the view that lymphadenectomy may potentially 
reduce the number of recurrences in the pelvis  [46, 47] , but intra-
abdominal spread and distant metastases predominate over iso-
lated pelvic recurrences  [18] . The SEER data also did not show any 
benefit of lymphadenectomy in relation to overall survival  [44] . 
Pelvic and para-aortic lymphadenectomy is therefore not a recom-
mended standard procedure in patients with LG-ESS.
 Adjuvant Systemic Therapy 
 The expression of steroid receptors and aromatases in LG-ESS 
suggests that adjuvant therapy with gestagens, GnRH analogues, or 
aromatase inhibitors should be effective. However, a benefit with 
these endocrine treatments has not been confirmed beyond doubt 
 [45, 46, 48] . In general, the data is limited to case series with small 
numbers of patients. The heterogeneous distribution pattern of the 
tumors and potential interaction with androgen receptors are 
thought to be responsible for the absence of response to gestagen 
and GnRH analogues, in spite of positive estrogen and progester-
one receptors  [33] . Gadducci et al.  [39]  argue in favor of a 24-
month course of adjuvant gestagen therapy with megestrol. Adju-
vant therapy with aromatase inhibitors for 5 years is recommended 
by some authors  [48] . The role of oophorectomy as an adjuvant 
ablative form of hormonal therapy remains unclear. For tumors 
that are not removed with healthy margins, adjuvant endocrine 
therapy is possibly indicated  [39, 49, 50] . The response rates are 
very high, at 82%, and remission periods of more than 10 years 
have been reported several times  [49] . In another study, the effi-
cacy of aromatase inhibitors and gestagens was compared in the 
adjuvant hormonal treatment of LG-ESS. In patients who were in 
stage I, gestagen therapy led to a recurrence-free survival (RFS) of 
306.2 months (95% confidence interval (CI) 259.7–352.6 months) 
compared to 153.1 months (95% CI 56.8–124.9 months) with aro-
matase inhibitor therapy and 90.8 months (95% CI 56.8–124.9 
months) without adjuvant endocrine therapy. However, due to se-
vere side effects such as hot flushes, depression, weight gain, and 
water retention, gestagen treatment was prematurely stopped 
much more frequently  [51] .
 Starting from FIGO stage III, adjuvant endocrine therapy in ac-
cordance with today’s standard may be considered but should not 
be carried out as a general rule  [4] . Medroxyprogesterone acetate 
or megestrol acetate or the aromatase inhibitors letrozole, anastro-
zole, or exemestane may be used  [4] .
 There are no valid data to show that adjuvant chemotherapy 
leads to any improvement in survival in patients with LG-ESS. In a 
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large observational study conducted by the National Cancer Data-
base, patients with FIGO I ESS received adjuvant chemotherapy. 
Among 2,414 patients with LG-ESS, 115 (4.8%) received chemo-
therapy. A total of 444 (33.4%) of 1,383 patients with HG-ESS also 
received adjuvant chemotherapy, and as many as 75.9% of them 
(337/444) received multi-agent chemotherapy. A longer survival 
period was only observed in association with chemotherapy in the 
group of patients with HG-ESS  [52] .
 Adjuvant Radiotherapy 
 In a large epidemiological study conducted in the United States 
including 3,650 patients with uterine sarcomas, a significant benefit 
of adjuvant radiotherapy to the pelvis (with or without brachyther-
apy) was observed in relation to locoregional RFS. The benefit was 
seen not only for the overall group, but also for the subgroup of pa-
tients with ESS (n = 312), with a 5-year locoregional RFS of 97 versus 
93% and an 8-year locoregional RFS of 97 versus 87%  [53] . However, 
another large study including 1,010 patients with ESS did not find 
that adjuvant pelvic radiotherapy had any positive effect on overall 
survival  [54] . A randomized phase III study including a total of 224 
patients with uterine sarcomas also included 28 patients with ESS. 
The patients were randomly assigned to an arm that received post-
operative adjuvant pelvic radiotherapy (51 Gy in 28 fractions over 5 
weeks), in comparison with observation alone  [55] . Although there 
was a reduction in the local recurrence rate (n = 14 vs. 24; p = 0.004), 
no effect on progression-free survival or overall survival was seen. 
The study did not conduct a subgroup analysis of patients with ESS.
 Postoperative radiotherapy in patients with ESS thus only ap-
pears to improve locoregional control, so that the medium-term 
and long-term side effects of pelvic irradiation need to be weighed 
carefully against what is in any case a good prognosis in relation to 
locoregional recurrences  [4] .
 Recurrences and Distant Metastases 
 The risk of recurrence in LG-ESS is 10–20%, and late recurrences 
after more than 10–30 years are characteristic of the disease  [25, 26] . 
Recurrences may appear locally in the vagina or lesser pelvis, or as 
distant metastases in the abdominal wall or lung  [56] . Only 40% of 
recurrences are limited exclusively to the lesser pelvis; 60% of them 
occur intra-abdominally, as distant metastases, or as a combination 
of all forms of dissemination  [57] . The median period to the appear-
ance of recurrences is 5.4–9.3 years in stages I and II and only 9 
months in stages III and IV (FIGO prior to 2009)  [57, 58] . Distant 
metastases and recurrences do not show any association with positive 
lymph nodes. Even in patients with negative lymph node status, re-
currence rates of up to 30% within 2 years are observed  [59] .
 Surgery, radiotherapy, and systemic therapy are regarded as po-
tential treatment options in patients with recurrences of and me-
tastases from uterine sarcomas  [60] , but only complete surgical re-
section is associated with an increased rate of cure and prolonged 
survival  [61–64] . After each recurrence or isolated metastasis, the 
extent to which complete resection is possible should therefore be 
checked. Due to the slow growth of the lesions, ESS can also be re-
peatedly successfully resected  [37] .
 Percutaneous radiotherapy can be used for palliative treatment 
in patients with local or locoregional recurrences of uterine sarco-
mas  [65, 66] . However, even in combination with chemotherapy, 
tumor progression occurs in more than 50% of the patients within 
2 years  [65–67] . Intraoperative radiotherapy or percutaneous irra-
diation can achieve a 3-year survival rate of 53% and a median sur-
vival period of 18 months after surgical treatment in patients with 
residual tumors  [54] .
 Due to the high level of expression of estrogen and progesterone 
receptors in LG-ESS, gestagens or aromatase inhibitors can be ad-
ministered in patients with postoperative residual tumor, inopera-
ble recurrences, or distant metastases  [49, 68–70] .
 Chemotherapy should only be used when other options have 
been exhausted. There are no studies showing any superiority of 
combination therapy over monotherapy. The data available are 
based only on case reports and phase II studies in which other 
types of uterine sarcoma were also treated  [71] .
 Due to the expression of epidermal growth factor receptor in 70% 
of ESS, treatment with monoclonal antibodies or tyrosine kinase in-
hibitors is conceivable  [18, 72] . There have been individual observa-
tions of complete remission during treatment with imatinib  [73] .
 Conclusion 
 Like the other uterine sarcomas, LG-ESS are a very rare tumor 
entity. The various diseases used to therefore be combined together 
in past research studies. In addition, the classification of endome-
trial stromal tumors presented difficulties for a considerable period 
so that earlier studies were not always able to distinguish precisely 
between LG-ESS, HG-ESS, and UUS. For LG-ESS, surgery with 
hysterectomy and adnexectomy is the first-line treatment. The 
benefits of lymphadenectomy or tumor debulking are unclear. En-
docrine therapies with gestagens and aromatase inhibitors are 
under discussion as adjuvant treatments in patients with advanced 
stages. Since it only provides locoregional control in patients who 
usually have a good prognosis with LG-ESS, radiotherapy needs to 
be carefully weighed up in relation to its side effects. Repeat sur-
gery is also the treatment of choice in cases of recurrence.
 In order to improve the treatment options available for LG-ESS, 
further research studies need to be conducted in which LG-ESS is 
considered as a distinct entity.
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